Association of cumulatively low or high serum calcium levels with mortality in long-term hemodialysis patients

Am J Nephrol. 2010;32(5):403-13. doi: 10.1159/000319861. Epub 2010 Sep 3.

Abstract

Background: The outcome-predictability of baseline and instantaneously changing serum calcium in hemodialysis patients has been examined. We investigated the mortality-predictability of time-averaged calcium values to reflect the 'cumulative' effect of calcium burden over time.

Methods: We employed a Cox model using up-to-5-year (7/2001-6/2006) time-averaged values to examine the mortality-predictability of cumulative serum calcium levels in 107,200 hemodialysis patients prior to the use of calcimimetics, but during the time where other calcium-lowering interventions, including lower dialysate calcium, were employed.

Results: Both low (<9.0 mg/dl) and high (>10.0 mg/dl) calcium levels were associated with increased mortality (reference: 9.0 to <9.5 mg/dl). Whereas mortality of hypercalcemia was consistent, hypocalcemia mortality was most prominent with higher serum phosphorus (>3.5 mg/dl) and PTH levels (>150 pg/ml). Higher paricalcitol doses shifted the calcium range associated with the greatest survival to the right, i.e. from 9.0 to <9.5 to 9.5 to <10.0 mg/dl. African-Americans exhibited the highest death hazard ratio of hypocalcemia <8.5 mg/dl, being 1.35 (95% CI: 1.22-1.49). Both a rise and drop in serum calcium over 6 months were associated with increased mortality compared to the stable group.

Conclusions: Whereas in hemodialysis patients cumulatively high or low calcium levels are associated with higher death risk, subtle but meaningful interactions with phosphorus, PTH, paricalcitol dose and race exist.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Black or African American
  • Bone Density Conservation Agents / administration & dosage
  • Cause of Death
  • Ergocalciferols / administration & dosage
  • Female
  • Humans
  • Hypercalcemia / complications*
  • Hypercalcemia / ethnology
  • Hypocalcemia / complications*
  • Hypocalcemia / ethnology
  • Kidney Failure, Chronic / blood*
  • Kidney Failure, Chronic / ethnology
  • Kidney Failure, Chronic / mortality*
  • Longitudinal Studies
  • Male
  • Middle Aged
  • Parathyroid Hormone / blood
  • Predictive Value of Tests
  • Proportional Hazards Models
  • Renal Dialysis*
  • Time Factors

Substances

  • Bone Density Conservation Agents
  • Ergocalciferols
  • Parathyroid Hormone
  • paricalcitol